Niagen Bioscience
NAGE
67 hedge funds and large institutions have $45.7M invested in Niagen Bioscience in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 6 closing their positions.
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
176% more capital invested
Capital invested by funds: $16.5M → $45.7M (+$29.1M)
98% more call options, than puts
Call options by funds: $513K | Put options by funds: $259K
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
26% more funds holding
Funds holding: 53 → 67 (+14)
2.04% more ownership
Funds ownership: 15.4% → 17.43% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$850K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$469K |
| 3 |
Goldman Sachs
New York
|
+$356K |
| 4 |
Jane Street
New York
|
+$341K |
| 5 |
HF
HRT Financial
New York
|
+$219K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$257K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$213K |
| 3 |
Renaissance Technologies
New York
|
-$158K |
| 4 |
Squarepoint
New York
|
-$47.1K |
| 5 |
Bank of New York Mellon
New York
|
-$28.9K |
NAGE Hedge Fund Activity: Q1 2024 in Review
67 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2024, worth a combined $45.7M — up 176% from $16.5M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new NAGE positions and 6 closed out — a net gain of 14 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, adding an estimated $850K. The largest seller was Citadel Advisors, cutting an estimated $257K.
- 67 institutional investors held Niagen Bioscience (NAGE) as of Q1 2024, up from 53 in Q4 2023.
- Funds reported $45.7M of Niagen Bioscience stock for Q1 2024, up 176% quarter-over-quarter.
- 20 funds opened new Niagen Bioscience positions in Q1 2024 and 6 closed out, a net change of +14 holders.
- The largest Niagen Bioscience buyer in Q1 2024 was Millennium Management, an estimated $850K added.
- The largest Niagen Bioscience seller in Q1 2024 was Citadel Advisors, an estimated $257K sold.
Based on aggregated 13F filings for Q1 2024.